TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Non-Inferiority Bladder Scan Study to Investigate Residual Urine After Use of Intermittent Catheters in Male Subjects
Brief Summary: Male intermittent catheters (ICs) range from 340-500 mm long, with the European standard minimum length being 360 mm for a catheter without a balloon and 275 mm for one with a balloon. This length is defined by hospital standards although it is known that the male urethra has an approximate maximum length of 29 cmA new intermittent catheter developed by Coloplast A/S is a 30-cm-long sterile, ready-to-use, hydrophilic-coated male catheter. There is a lack of clinical data documenting that male ICs that are shorter and more or less flexible than standard catheters can sufficiently empty the bladder of male subjects. This will be tested using ultrasound to measure residual urine in the bladder following catheterisation with new product and standard length catheter.


Options:
A: Arm Label: SpeediCath catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: SpeediCath | Arm Label: Test product; Type: EXPERIMENTAL; Interventions: Device: Test Catheter - SpeediCath Compact Male | Intervention Type: DEVICE; Name: Test Catheter - SpeediCath Compact Male; Assigned to Arm(s): Test product | Intervention Type: DEVICE; Name: SpeediCath; Assigned to Arm(s): SpeediCath catheter
B: Arm Label: Compact catheter; Type: EXPERIMENTAL; Interventions: Device: SpeediCath Compact | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard care | Intervention Type: DEVICE; Name: SpeediCath Compact; Assigned to Arm(s): Compact catheter | Intervention Type: DEVICE; Name: Standard care; Assigned to Arm(s): Standard Care
C: Arm Label: 30 cm Intermittent Catheter; Type: EXPERIMENTAL; Interventions: Device: 30 cm Intermittent Catheter | Arm Label: 40 cm Intermittent Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: 40 cm Intermittent Catheter | Intervention Type: DEVICE; Name: 30 cm Intermittent Catheter; Assigned to Arm(s): 30 cm Intermittent Catheter | Intervention Type: DEVICE; Name: 40 cm Intermittent Catheter; Assigned to Arm(s): 40 cm Intermittent Catheter
D: Arm Label: Single-use catheter; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-use catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with 0.5% benzalkonium chloride; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Arm Label: Reused catheter with soap and water; Type: EXPERIMENTAL; Interventions: Procedure: Reused catheter, Diagnostic Test: Urine culture | Intervention Type: PROCEDURE; Name: Single-use catheter; Assigned to Arm(s): Single-use catheter | Intervention Type: PROCEDURE; Name: Reused catheter; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water | Intervention Type: DIAGNOSTIC_TEST; Name: Urine culture; Assigned to Arm(s): Reused catheter with 0.5% benzalkonium chloride, Reused catheter with soap and water, Single-use catheter

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation on the Diagnostic and Predictive Value of Bilateral Bispectral Index (BIS)-Monitoring in Cardiac Surgery
Brief Summary: The bispectral index (BIS) is derived from a single-channel electroencephalogram (EEG) and provides information on the anaesthetic depth. Recently, a bilateral two-channel EEG-sensor has been introduced to monitor the BIS on both cerebral hemispheres. In some patients significant left-right differences may occur, whereas no relevant side differences are expected in the majority of patients.

The aim of this study is to

* investigate the incidence, duration and degree of left-right BIS differences
* examine the relation between BIS differences and occurrence of cognitive deficits


Options:
A: Arm Label: EEG guided protocol; Type: EXPERIMENTAL; Interventions: Device: a pragmatic EEG-guided anesthetic protocol | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: a pragmatic EEG-guided anesthetic protocol; Assigned to Arm(s): EEG guided protocol
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
C: N/A
D: Arm Label: desflurane and sevoflurane; Type: N/A; Interventions: Other: The intervention will be Mini-Mental Status Examination (MMSE) | Intervention Type: OTHER; Name: The intervention will be Mini-Mental Status Examination (MMSE); Assigned to Arm(s): desflurane and sevoflurane

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial
Brief Summary: Minimally invasive surgery has become the standard treatment for many gynecologic disease processes. In the last decade, numerous studies have demonstrated that laparoscopic approaches to various gynecologic oncology conditions-particularly for early-stage endometrial and cervical cancers as well as select pelvic masses-is feasible and results in shorter hospital stays, improved quality of life and comparable surgical and oncologic outcomes to abdominal staging \[1-5\].For instance, the typical gynecologic robotic surgical procedure will require Two to three 5-mm ports and one 12-mm laparoscopic ports. Recently, an even less invasive alternative to conventional laparoscopy surgery has been developed: laparoendoscopic single-site surgery (LESS), also known as single-port surgery. Single port laparoscopy is an attempt to further enhance the cosmetic benefits of minimally invasive surgery while minimizing the potential morbidity associated with multiple incisions. However, to our knowledge, there are no randomize control trial to evaluate of single port or multiple ports laparoscopic surgery in gynecologic disorders. The purpose of this study was to assess the feasibility of SPA-LAVH in the treatment of benign uterine disease.


Options:
A: Arm Label: Robot-assisted; Type: EXPERIMENTAL; Interventions: Procedure: Hysterectomy | Arm Label: Laparoscopic Hysterectomy; Type: EXPERIMENTAL; Interventions: Procedure: Hysterectomy | Intervention Type: PROCEDURE; Name: Hysterectomy; Assigned to Arm(s): Laparoscopic Hysterectomy, Robot-assisted
B: Arm Label: single-port LAVH; Type: EXPERIMENTAL; Interventions: Procedure: single-port LAVH | Intervention Type: PROCEDURE; Name: single-port LAVH; Assigned to Arm(s): single-port LAVH
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Laparoscopic Hysterectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Robot-assisted (Da Vinci®) laparoscopic hysterectomy | Intervention Type: PROCEDURE; Name: Conventional Laparoscopic Hysterectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Robot-assisted (Da Vinci®) laparoscopic hysterectomy; Assigned to Arm(s): 2
D: Arm Label: Robot assisted laparoscopic hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Robot assisted laparoscopic hysterectomy | Arm Label: Abdominal hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Abdominal hysterectomy; Assigned to Arm(s): Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Robot assisted laparoscopic hysterectomy; Assigned to Arm(s): Robot assisted laparoscopic hysterectomy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial
Brief Summary: The purpose of this study is to better characterize differences in mood, attention, brain activation patterns underlying the beneficial effects of pharmacological treatments previously demonstrated to be help individuals successfully quit tobacco smoking. Smokers will be randomly assigned to one of three treatments: 1) bupropion sustained release (SR), 2) nicotine patch, or 3) placebo patches plus pills across a 45-day period with a 3-week intensive post-treatment follow-up. In addition, 20 percent of the subjects will be randomized to a delayed-quit control group.


Options:
A: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
D: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patch | Arm Label: Placebo Patch and Placebo Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Patch and Placebo Pill | Arm Label: Delayed-quit control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch | Intervention Type: DRUG; Name: Placebo Patch and Placebo Pill; Assigned to Arm(s): Placebo Patch and Placebo Pill

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial
Brief Summary: The purpose of this study is to better characterize differences in mood, attention, brain activation patterns underlying the beneficial effects of pharmacological treatments previously demonstrated to be help individuals successfully quit tobacco smoking. Smokers will be randomly assigned to one of three treatments: 1) bupropion sustained release (SR), 2) nicotine patch, or 3) placebo patches plus pills across a 45-day period with a 3-week intensive post-treatment follow-up. In addition, 20 percent of the subjects will be randomized to a delayed-quit control group.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Placebo, Varenicline
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmacist-delivered group program for smoking cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Brief standard care session for smoking cessation delivered over the telephone | Intervention Type: OTHER; Name: Pharmacist-delivered group program for smoking cessation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Brief standard care session for smoking cessation delivered over the telephone; Assigned to Arm(s): 2
C: Arm Label: Extended Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Extended Varenicline Pretreatment | Arm Label: Short-term Varenicline Pretreatment; Type: EXPERIMENTAL; Interventions: Drug: Short-term Varenicline Pretreatment | Intervention Type: DRUG; Name: Extended Varenicline Pretreatment; Assigned to Arm(s): Extended Varenicline Pretreatment | Intervention Type: DRUG; Name: Short-term Varenicline Pretreatment; Assigned to Arm(s): Short-term Varenicline Pretreatment
D: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patch | Arm Label: Placebo Patch and Placebo Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Patch and Placebo Pill | Arm Label: Delayed-quit control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch | Intervention Type: DRUG; Name: Placebo Patch and Placebo Pill; Assigned to Arm(s): Placebo Patch and Placebo Pill

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Music Therapy on Women's Anxiety Before and During Cesarean Delivery
Brief Summary: The purpose of the study is to determine if listening to your choice of music with a portable mp3 player before and after a cesarean section for delivery of a baby will decrease the patient's anxiety level.


Options:
A: Arm Label: Music therapy; Type: EXPERIMENTAL; Interventions: Other: Music group, Other: Non music group | Arm Label: No music group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Music group; Assigned to Arm(s): Music therapy | Intervention Type: OTHER; Name: Non music group; Assigned to Arm(s): Music therapy
B: Arm Label: Narcotic counseling script; Type: EXPERIMENTAL; Interventions: Behavioral: Narcotic counseling script | Arm Label: Post-partum depression counseling script; Type: SHAM_COMPARATOR; Interventions: Behavioral: Post-partum depression counseling script | Intervention Type: BEHAVIORAL; Name: Narcotic counseling script; Assigned to Arm(s): Narcotic counseling script | Intervention Type: BEHAVIORAL; Name: Post-partum depression counseling script; Assigned to Arm(s): Post-partum depression counseling script
C: Arm Label: Binder; Type: EXPERIMENTAL; Interventions: Device: Elastic abdominal binder | Arm Label: No binder; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Elastic abdominal binder; Assigned to Arm(s): Binder
D: Arm Label: Repeat C/S Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Repeat C/S Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Alkantis | Arm Label: Primary C/S - Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primary C/S Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Alkantis | Intervention Type: OTHER; Name: Alkantis; Assigned to Arm(s): Primary C/S Treatment, Repeat C/S Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prolonged Exposure for PTSD Among OIF/OEF Personnel: Massed vs. Spaced Trials
Brief Summary: The purpose of this study is 1) to evaluate whether massing 10 PE sessions in 2 weeks (massed trials; M-PE) is more efficacious than Minimal Contact control (MCC); 2) whether the massed sessions format retains the efficacy of treatment compared to 10 PE sessions spaced over 8 weeks (spaced trials; S-PE), and 3) to evaluate for the first time the efficacy of the 10 PE sessions delivered in 8 weeks in an active duty population by comparing it to an active comparison condition, Present-Centered Therapy (PCT).


Options:
A: Arm Label: Minimal Contact Control; Type: OTHER; Interventions: Behavioral: Minimal Contact Control | Arm Label: PE-Massed; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure Therapy - Massed | Arm Label: PE-Spaced; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolonged Exposure Therapy - Spaced | Arm Label: Present-Centered Therapy (PCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy - Massed; Assigned to Arm(s): PE-Massed | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy - Spaced; Assigned to Arm(s): PE-Spaced | Intervention Type: BEHAVIORAL; Name: Minimal Contact Control; Assigned to Arm(s): Minimal Contact Control | Intervention Type: BEHAVIORAL; Name: Present-Centered Therapy; Assigned to Arm(s): Present-Centered Therapy (PCT)
B: Arm Label: Arm 1: Mindfulness-Based Stress Reduction (MBSR); Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction (MBSR) | Arm Label: Arm 2: Present-Centered Group Therapy (PCGT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Group Therapy (PCGT) | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction (MBSR); Assigned to Arm(s): Arm 1: Mindfulness-Based Stress Reduction (MBSR) | Intervention Type: BEHAVIORAL; Name: Present-Centered Group Therapy (PCGT); Assigned to Arm(s): Arm 2: Present-Centered Group Therapy (PCGT)
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Present-Centered Therapy; Assigned to Arm(s): Arm 2
D: Arm Label: Mantram Repetition Program (MRP); Type: EXPERIMENTAL; Interventions: Behavioral: Mantram Repetition Program (MRP) | Arm Label: Present Centered Therapy (PCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present Centered Therapy (PCT) | Intervention Type: BEHAVIORAL; Name: Mantram Repetition Program (MRP); Assigned to Arm(s): Mantram Repetition Program (MRP) | Intervention Type: BEHAVIORAL; Name: Present Centered Therapy (PCT); Assigned to Arm(s): Present Centered Therapy (PCT)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clamp-Crushing vs. Stapler Hepatectomy for Transection of the Parenchyma in Elective Hepatic Resection: CRUNSH - A Randomized Controlled Trial
Brief Summary: There is clinical uncertainty and ongoing discussion among liver surgeons regarding the optimal method of parenchymal transection in patients undergoing elective hepatic resection. While the clamp-crushing technique still represents the reference technique for routine liver resections, transection of liver parenchyma using vascular staplers may offer a new and safe technique potentially reducing intraoperative blood loss, operation time as well as peri-operative morbidity. As morbidity of patients undergoing hepatic resection remains high, approaches to lower peri-operative complications are urgently required. Due to the lack of evidence it has to be evaluated, if the technique of stapler hepatectomy decreases intraoperative blood loss as a highly relevant predictor of peri-operative complications, patients' hospital stay and finally health care expenditures. These advantages would favor stapler hepatectomy to be applied in routine liver resections. As RCTs are generally considered to generate the most valid scientific evidence on a treatment's effects, the present trial evaluates potential benefits of stapler hepatectomy in a randomized fashion.


Options:
A: Arm Label: Clamp-Crushing technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crushing technique | Arm Label: BiClamp forceps hepatectomy; Type: EXPERIMENTAL; Interventions: Device: BiClamp forceps | Intervention Type: PROCEDURE; Name: Clamp-Crushing technique; Assigned to Arm(s): Clamp-Crushing technique | Intervention Type: DEVICE; Name: BiClamp forceps; Assigned to Arm(s): BiClamp forceps hepatectomy
B: Arm Label: Clamp-Crush technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crush technique | Arm Label: Stapler hepatectomy; Type: EXPERIMENTAL; Interventions: Procedure: Stapler hepatectomy | Intervention Type: PROCEDURE; Name: Clamp-Crush technique; Assigned to Arm(s): Clamp-Crush technique | Intervention Type: PROCEDURE; Name: Stapler hepatectomy; Assigned to Arm(s): Stapler hepatectomy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: rThrombin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: bovine thrombin | Intervention Type: BIOLOGICAL; Name: rThrombin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: bovine thrombin; Assigned to Arm(s): 2
D: Arm Label: Standard fluid management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard fluid management | Arm Label: Goal directed fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Goal directed fluid therapy with the Edwards EV1000 system | Intervention Type: PROCEDURE; Name: Standard fluid management; Assigned to Arm(s): Standard fluid management | Intervention Type: DEVICE; Name: Goal directed fluid therapy with the Edwards EV1000 system; Assigned to Arm(s): Goal directed fluid therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 9-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
Brief Summary: The purpose of the study is to learn if long-term treatment with DVS SR is safe for treating the pain and other symptoms associated with diabetic peripheral neuropathy.


Options:
A: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: cognitive behavioral therapy | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: desipramine hydrochloride, Behavioral: cognitive behavioral therapy | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: benztropine mesylate 0.125 mg daily | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 3 | Intervention Type: BEHAVIORAL; Name: cognitive behavioral therapy; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: benztropine mesylate 0.125 mg daily; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: desipramine hydrochloride; Assigned to Arm(s): Arm 1
C: Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine 60 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: DVS SR Open Label; Type: OTHER; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): DVS SR Open Label

Answer: D